Recently, the Beijing Municipal Bureau of Economy and Information Technology released the Notice on the Announcement of the New List of Beijing Enterprise Technology Centers for 2024. Following a rigorous review, evaluation, and public disclosure of the application materials, AccuMedical was honored to be included on the list.
The title of "Beijing Enterprise Technology Center" is an authoritative recognition awarded to enterprise technology centers that demonstrate strong innovation capabilities, effective innovation mechanisms, significant leadership, and meet specified criteria. It is a highly prestigious qualification for provincial and ministerial-level R&D platforms, aligning with the requirements of innovation-driven development and economic structural adjustment.
As an innovative medical device company dedicated to the field of neurointervention, AccuMedical adheres to a forward-looking R&D principle guided by clinical insights, focusing on independent innovation in core technologies and products. By improving satisfaction for both physicians and patients, reducing surgical risks, and enhancing outcomes, the company continues to lead advancements in neurointerventional treatment.
In recent years, AccuMedical has been awarded honors such as "National High-Tech Enterprise" and "National-Level 'Little Giant' Enterprise." Being recognized as a Beijing Enterprise Technology Center further reflects the government’s acknowledgment and affirmation of AccuMedical's R&D innovation capabilities and technological achievements.
Moving forward, the company will leverage this recognition as an opportunity to uphold the vision of technological self-reliance and strength. Guided by the corporate value of " Treat, as our own" AccuMedical will continue addressing unmet clinical needs in the field of cerebrovascular diseases, improving the accessibility of innovative medical technologies, and striving to meet the health needs of global cerebrovascular patients.
